Price Chart

Executive Summary

Passage Bio filed an amended S-4 (S-4/A) detailing its proposed reverse merger with Remix Therapeutics, where Remix will become a wholly owned subsidiary and Passage Bio will change its name to Remix Therapeutics, Inc. Pre-merger Passage Bio equity holders are expected to own approximately 6% of the combined company, while Remix equity holders and concurrent financing investors are expected to own approximately 65% and 29%, respectively. The concurrent financing, via a Subscription Agreement and convertible notes, is expected to raise approximately $100 million in gross proceeds, with the closing conditioned on the merger, and Passage Bio's remaining assets from its GM1 and MLD programs are being packaged into contingent value rights (CVRs) for current Passage Bio stockholders that may expire worthless.

Key Facts

• Pre-merger Passage Bio equity holders will own approximately 6% of the combined company; Remix equity holders ~65%, concurrent financing investors ~29%.
• Concurrent financing expected to raise ~$100.0 million, but is conditioned on merger closing.
• Passage Bio equity holders will receive one CVR per share for proceeds from Gemma Biotherapeutics license arrangements (GM1 and MLD), which may expire worthless.
• Passage Bio's net cash at closing is anticipated to be approximately $10.9 million, but its valuation for the exchange ratio is based on an assumed $5.0 million net cash; Passage Bio's net cash is nearly fully depleted beyond immediate obligations.
• Passage Bio has wound down development programs, reduced workforce by ~75%, and has incurred net losses of $15.4 million and $24.8 million in the six months ended June 30, 2026 and 2025, respectively.
• Passage Bio has an accumulated deficit of $720.1 million as of June 30, 2026.
• Passage Bio currently only has ~$46.3 million in cash as of Dec 31, 2025, and has no path to revenue.
• Merger agreement includes a termination fee of $1.5 million payable by Passage Bio under certain circumstances.
• Remix has only one clinical-stage asset, REM-422, in Phase 1/2 for AML/HR-MDS/ACC, is a pre-revenue clinical-stage biotech, and has a going concern uncertainty.
• Lock-up agreements restrict sales of combined company stock for 180 days post-closing for ~99% of Remix capital stock holders.

Financial Impact

Passage Bio stockholders diluted to ~6% ownership; net cash at closing anticipated ~$10.9 million; combined company expected to have ~$100M gross proceeds from concurrent financing but equity value of Remix only $226M vs zero revenue; CVRs for GM1/MLD may yield nothing.

Risk Factors

• Transaction may not close; if terminated, Passage Bio may liquidate with minimal or zero distribution to shareholders.
• CVRs tied to Gemma sublicenses may never pay out (GM1 payment deadline July 31, 2028; MLD deadline Dec 31, 2027).
• Remix has going concern uncertainty in its own standalone financials.
• Combined company will face significant integration challenges and cash burn as a clinical-stage entity.
• If Concurrent Financing does not close, combined company will have insufficient capital.
• Post-merger stock (RMTX) is subject to lock-up expiration 180 days after close, adding selling pressure.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

US Market Status